Merck’s ( MRK ) plan to seek approval of the U.S. FDA for its investigational cardiovascular drug Tredaptive early next year seems to be on the right track as researchers plan to announce
More:
Merck Updates: Outcome of Large Clinical Study On Tredaptive Soon